1265-P: To What Extent Do Carbohydrate Intake, Physical Activity, and Meal Timing Impact Two-Hour Postprandial Glucose in Pregnancy Hyperglycemia?

by sugaradmin



Introduction and Objective: Managing carbohydrate intake and physical activity (PA) are recommended for individuals with pregnancy hyperglycemia, but the concurrent impact of these behaviors and meal timing on postprandial glucose levels has not been explored.Methods: Fourteen participants with gestational glucose intolerance (GGI) and 2 with GDM from the Time to Move Randomized Crossover Trial (ClinicalTrials.gov #NCT06125704) wore blinded Dexcom G6 Pro continuous glucose monitoring devices; completed timestamped photo-upload assisted, 24-hr dietary recalls; and wore Actigraph CentrePoint Insight Watch PA monitoring devices in the third trimester. This analysis explored differences in mean 2-hr postprandial glucose following breakfast (between 5-9am) compared to dinner (between 4-8pm), across 3 observation-days. Estimates from Proc Mixed in SAS v9.4 were adjusted for meal-specific carbohydrate intake (dichotomized at the 75th percentile) and postprandial PA (i.e., completion of trial assigned, moderate intensity walking or stepping, within 30-40 minutes of the meal).Results: After adjusting for meal-specific carbohydrate intake and postprandial PA, mean 2-hr postprandial glucose was 105.87 mg/dl (SE 5.78) for breakfast compared to 108.73 mg/dl (SE 5.77) for dinner (p =.41). Adjusted mean 2-hr postprandial glucose was 103.95 mg/dl (SE 5.72) after meals with carbohydrate in the lower quartiles compared to 110.65 mg/dl (SE 5.90) after high carbohydrate meals (p=.08), and 106.10 mg/dl (SE 6.02) for postprandial PA compared to 108.49 mg/dl (SE 5.60) for no PA (p =.52).Conclusion: Additional data are pending and will improve the precision of estimated differences, but this preliminary analysis does not support an independent association between meal timing and mean 2-hr postprandial glucose levels in free-living individuals with GDM or GGI.

Disclosure

J.E. Lewis: None. B.R. Hallenbeck: None. H. Raynor: None. S.E. Crouter: None. J.I. Miller: None. S. Yousefi: None. N. Zite: Research Support; Merck & Co., Inc. W. Schoutko: None. K.B. Fortner: Other Relationship; Pfizer Inc. J.M. Maples: None. S.F. Ehrlich: None.

Funding

American Diabetes Association (11-22-ICTSN-29)



Source link